Articles from Aerin Medical Inc.

Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the launch of its next-generation RhinAer® device as well as UnitedHealthcare’s Medicare Advantage policy now covering RhinAer for treatment of the posterior nasal nerve (CPT 31242) effective immediately. The temperature- and impedance-controlled radiofrequency RhinAer+ device treats the posterior nasal nerve (PNN) and comprehensively targets multiple anatomic contributors to chronic rhinitis, a chronic condition with substantial adverse health impact, along with sleep quality and worker productivity consequences.

Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the publication of long-term results from a multicenter study evaluating the safety and efficacy of RhinAer, which uses temperature-controlled radiofrequency (TCRF) to target the posterior nasal nerve (PNN) in patients with chronic rhinitis (CR). Published in the American Journal of Rhinology & Allergy, the study followed patients for three years post-treatment, reporting sustained improvements in symptoms, quality of life, and medication burden with no serious device- or procedure-related adverse events.

Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the appointment of Lucas Buchanan to its Board of Directors. Mr. Buchanan will serve as an independent director, bringing important expertise and strategic perspective to guide Aerin’s significant value creation.

Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna’s list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patients suffering from the debilitating effects of chronic rhinitis.

Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the publication of positive three-year outcomes from the AERWAY clinical study that underscore the durability of the VivAer procedure. The prospective, single-arm, multicenter clinical study, published in OTO Open, confirms that VivAer provides consistent and long-lasting symptom relief for patients suffering from nasal airway obstruction (NAO) due to nasal valve collapse (NVC).

Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the publication of positive three-year follow-up results from the RHINTRAC study in the International Forum of Allergy & Rhinology (IFAR). The randomized controlled trial evaluated the safety and efficacy of temperature-controlled radiofrequency (TCRF) ablation of the posterior nasal nerve (PNN) using RhinAer. This latest published study further strengthens Aerin’s established and extensive body of clinical evidence supporting the therapy’s long-term benefits, including sustained symptom relief, decreased medication use, and meaningful improvements in quality of life.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced the publication of positive 24-month results from RHINTRAC, a randomized, sham-controlled clinical trial, in the International Forum of Allergy & Rhinology (IFAR). These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years. These findings build on the previously published results of two separate studies that also demonstrated significant, sustained improvement with RhinAer treatment.1,2

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced that Rhinology Journal has published positive two-year outcomes from the VATRAC trial. The study showed a single in-office treatment with VivAer® resulted in sustained improvement in symptoms of nasal airway obstruction (NAO) caused by nasal valve collapse, and reduced both daytime sleepiness and the use of medications and mechanical aids. Previously published three-month results of the randomized controlled trial demonstrated that treatment with VivAer was safe and superior to a sham procedure.1

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced the publication of two-year positive results from the RELIEF clinical trial in The Laryngoscope. RELIEF demonstrated that a single procedure with RhinAer®, a temperature-controlled, radiofrequency technology, resulted in sustained improvements in chronic rhinitis symptoms, including post-nasal drip and chronic cough, and quality of life through two years along with a substantial decrease in chronic rhinitis medication usage.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced the publication of positive two-year follow-up data from the AERWAY trial for patients with severe or extreme nasal airway obstruction (NAO) due to nasal valve collapse (NVC). Results featured in Laryngoscope Investigative Otolaryngology showed a significant and long-term improvement in NAO symptom burden.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, supports the recent American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) position statement. The statement recognizes nasal valve repair as “a distinct surgical procedure that can improve nasal obstruction symptoms for appropriately selected patients.” The Academy notes that office-based techniques, including radiofrequency treatment, can stabilize the nasal valve, optimize nasal valve collapse (NVC) patient outcomes, and be performed either as a standalone procedure or in combination with other procedures to potentially avoid multiple surgeries.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that the Centers for Medicare and Medicaid Services (CMS) assigned physician and facility payment for a new Category I Current Procedural Terminology (CPT®) code that includes the use of VivAer® to repair nasal valve collapse (NVC) when performed in the office and outpatient surgical settings. The new code goes into effect on January 1, 2023.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel accepted the application for a new Category I CPT code to report endoscopic destruction of the posterior nasal nerve using radiofrequency (RF) ablation. This information was released by the AMA in the Summary of Panel Actions from the September CPT Editorial Panel meeting. The new code will become effective on January 1, 2024, and describes the procedure performed by ENT physicians when treating their patients with Aerin Medical’s RhinAer®. The RhinAer Stylus precisely applies RF energy to overactive nerves in the back of the nose, reducing chronic rhinitis symptoms.

Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of a next-generation RhinAer® stylus. RhinAer is a non-invasive, temperature-controlled radiofrequency technology that durably treats the causes of rhinorrhea (runny nose), post-nasal drip and congestion associated with chronic rhinitis in a single session. The new RhinAer is designed to provide physicians with improved visualization, easier access and tissue apposition, especially in patients with narrow nasal airways.

Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced that JAMA Otolaryngology – Head & Neck Surgery published positive 12-month active treatment group outcomes from the VATRAC trial. Participants in the index active and crossover active treatment arms of the study showed durable improvement in symptoms of nasal airway obstruction (NAO) caused by nasal valve collapse (NVC) over baseline at 12 months following a single treatment with VivAer®. Previously published three-month results of the randomized controlled portion of the trial demonstrated that treatment with VivAer was safe and superior to a sham procedure.1

Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive results from the RELIEF clinical trial in the American Journal of Rhinology & Allergy. RELIEF demonstrated that treatment yielded a clinically significant improvement in all chronic rhinitis symptoms and quality-of-life (QoL) at three- and six-months following RhinAer® treatment. Additionally, the study demonstrated that the procedure was well-tolerated by patients.

Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive 12-month results from RHINTRAC, a randomized, sham-controlled clinical trial, in the International Forum of Allergy & Rhinology (IFAR). These results for the trial’s active treatment arm showed that chronic rhinitis symptoms continued to improve through 12 months after treatment with RhinAer®. The findings build on a previous publication demonstrating treatment with RhinAer was safe and superior to a sham procedure control.1

Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced that the International Forum of Allergy & Rhinology published positive four-year results from a VivAer® clinical trial. The results showed the long-term durability of VivAer® treatment for those with nasal airway obstruction (NAO) due to nasal valve collapse (NVC). In the follow-up study, patients experienced significant and sustained improvement in symptoms of NAO through four years following a single treatment of NVC with VivAer. The publication adds to a growing body of evidence supporting the safety and efficacy of VivAer.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced it has recently closed a $60 million equity financing. The financing was led by new investor Ally Bridge Group, with all existing major investors KCK MedTech, Questa Capital and OrbiMed also participating. The company intends to use the proceeds to scale commercialization and expand market access to meet the demand from physicians and their patients.

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced the publication in Allergy and Rhinology of positive two-year results from a trial evaluating the safety and efficacy of RhinAer® in patients with chronic rhinitis. Data from the trial demonstrated that treatment with RhinAer to the posterior nasal nerve (PNN) is safe and provides significant, durable symptom improvement for both chronic non-allergic and allergic rhinitis patients.

Aerin Medical Inc., a company dedicated to providing Ear Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced key events at upcoming annual meetings for the American Rhinologic Society (ARS 2021) and American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF 2021).

Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced the publication of positive results from the RHINTRAC clinical trial in OTO Open. Three-month data from the randomized sham-controlled trial demonstrated that treatment with RhinAer is safe and provides significant symptom improvement superior to control for patients with chronic rhinitis. RhinAer is an innovative, temperature-controlled radiofrequency (RF) technology used to disrupt nerve signals that cause chronic rhinitis symptoms, such as constant runny nose and postnasal drip. The RHINTRAC study reinforces RhinAer safety and efficacy established by recently published one-year pivotal study results.

Aerin Medical Inc., a company dedicated to providing Ear Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced that the American Journal of Rhinology & Allergy has published positive one-year results from a trial evaluating the safety and efficacy of RhinAer® in patients with chronic rhinitis. RhinAer is an innovative, temperature-controlled, radiofrequency technology used to disrupt nerve signals that cause chronic rhinitis symptoms. Following a single treatment with RhinAer, symptom severity significantly decreased in the first two weeks and remained low through the one-year follow-up.

Aerin Medical Inc., a company dedicated to providing Ear Nose and Throat (ENT) physicians non-invasive solutions for the treatment of chronic nasal airway conditions, today announced that the International Forum of Allergy and Rhinology has published three-month results online from the VATRAC trial, confirming the safety and efficacy of VivAer® for the treatment of nasal airway obstruction (NAO) caused by nasal valve collapse (NVC). In the study, those treated with VivAer showed significant improvement in nasal obstruction symptoms compared to the control group. This is the first randomized controlled trial of a non-invasive, radiofrequency treatment of NVC.